Free Trial

Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson logo
$155.17 -0.33 (-0.21%)
(As of 11/22/2024 ET)

Johnson & Johnson - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
7
Buy
8

Based on 15 Wall Street analysts who have issued ratings for Johnson & Johnson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 7 have given a hold rating, and 8 have given a buy rating for JNJ.

Consensus Price Target

$175.94
13.38% Upside
According to the 15 analysts' twelve-month price targets for Johnson & Johnson, the average price target is $175.94. The highest price target for JNJ is $215.00, while the lowest price target for JNJ is $150.00. The average price target represents a forecasted upside of 13.38% from the current price of $155.17.
Get the Latest News and Ratings for JNJ and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Johnson & Johnson and its competitors.

Sign Up

JNJ Analyst Ratings Over Time

TypeCurrent Forecast
11/25/23 to 11/24/24
1 Month Ago
10/26/23 to 10/25/24
3 Months Ago
8/27/23 to 8/26/24
1 Year Ago
11/25/22 to 11/25/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$175.94$175.93$173.21$169.19
Forecasted Upside13.38% Upside9.35% Upside5.20% Upside10.94% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold

JNJ Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JNJ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Johnson & Johnson Stock vs. The Competition

TypeJohnson & JohnsonMedical CompaniesS&P 500
Consensus Rating Score
2.53
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside13.38% Upside27,073.48% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent JNJ News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2024Wolfe Research
3 of 5 stars
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$190.00+25.12%
11/6/2024Guggenheim
2 of 5 stars
 Boost TargetNeutral ➝ Neutral$156.00 ➝ $162.00+2.40%
10/16/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$180.00 ➝ $185.00+12.43%
10/16/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$215.00 ➝ $215.00+30.70%
10/16/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$163.00 ➝ $166.00+0.91%
10/16/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$178.00 ➝ $181.00+10.28%
10/16/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$169.00 ➝ $175.00+6.62%
7/23/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/23/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$160.00 ➝ $150.00-2.75%
7/19/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$160.00 ➝ $155.00+0.27%
7/18/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$161.00 ➝ $171.00+9.10%
7/18/2024TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$195.00 ➝ $185.00+18.03%
7/18/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$195.00 ➝ $185.00+18.38%
4/18/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$169.00 ➝ $170.00+17.43%
4/17/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$180.00 ➝ $170.00+17.96%
1/3/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$172.00 ➝ $175.00+8.93%
12/1/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$167.00 ➝ $180.00+16.39%
10/12/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$158.00 ➝ $162.00+3.73%
8/4/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$167.00 ➝ $170.00-0.42%
7/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$175.00 ➝ $180.00+5.75%
7/21/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$165.00 ➝ $175.00+3.92%
7/21/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$170.00 ➝ $175.00+3.92%
2/6/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$55.00 ➝ $52.00-68.17%
1/20/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$194.00 ➝ $186.00+9.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:31 PM ET.


Should I Buy Johnson & Johnson Stock? JNJ Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 21, 2024. Please send any questions or comments about these Johnson & Johnson pros and cons to contact@marketbeat.com.

Johnson & Johnson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Johnson & Johnson:

  • Johnson & Johnson recently reported earnings per share of $2.42, exceeding analyst expectations of $2.21, indicating strong financial performance and effective management.
  • The stock is currently trading at $155.66, which is near its 1-year high of $168.85, suggesting potential for further appreciation in value.
  • Institutional investors hold 69.55% of the stock, reflecting strong confidence in the company's stability and growth prospects.
  • Analysts have a consensus rating of "Moderate Buy" with a price target of $175.94, indicating positive sentiment and potential for price increases.
  • Johnson & Johnson has demonstrated a solid revenue growth of 5.2% year-over-year, showcasing its ability to expand and adapt in a competitive market.

Johnson & Johnson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Johnson & Johnson for these reasons:

  • Despite recent growth, the stock has experienced volatility, with a significant drop from its 1-year high, which may concern risk-averse investors.
  • The company's debt-to-equity ratio stands at 0.45, which, while manageable, indicates some reliance on debt financing that could pose risks in economic downturns.
  • Recent selling by institutional investors, such as King Luther Capital Management Corp, which reduced its holdings by 1.4%, may signal a lack of confidence among some large stakeholders.
  • Market conditions and regulatory challenges in the healthcare sector could impact future performance, making it a less stable investment option.
  • Johnson & Johnson's price-to-earnings (P/E) ratio of 22.09 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.

JNJ Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Johnson & Johnson is $175.94, with a high forecast of $215.00 and a low forecast of $150.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last twelve months. There are currently 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JNJ shares.

According to analysts, Johnson & Johnson's stock has a predicted upside of 13.38% based on their 12-month stock forecasts.

Johnson & Johnson has been rated by research analysts at Cantor Fitzgerald, Citigroup, Guggenheim, Morgan Stanley, Royal Bank of Canada, Wells Fargo & Company, and Wolfe Research in the past 90 days.

Analysts like Johnson & Johnson less than other "medical" companies. The consensus rating score for Johnson & Johnson is 2.53 while the average consensus rating score for "medical" companies is 2.80. Learn more on how JNJ compares to other companies.


This page (NYSE:JNJ) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners